The intestine performs one of biology’s most remarkable balancing acts. It must allow the selective passage of nutrients while blocking potentially harmful substances, a feat achieved through a multilayered barrier composed of specialized epithelial cells called enterocytes, tight junctions that govern the spaces between cells, a thick mucus layer, and an intricate mucosal immune system. Under normal conditions, most macromolecules, including proteins, peptides, and synthetic polymers, are either degraded before they can be absorbed or excluded from passage altogether. Their sheer size prevents them from squeezing through the tight junctions of the paracellular pathway, and their hydrophilic, water-loving nature makes it difficult for them to dissolve into and cross lipid cell membranes via the transcellular route. Only in special circumstances, such as in newborns or in states of inflammation and mucosal damage, can endocytosis or increased paracellular permeability permit larger compounds to slip through.

PEGs, also known as macrogols, are a family of synthetic polyether polymers produced by polymerizing ethylene oxide with water or ethylene glycol. Their behavior in the gut depends almost entirely on molecular weight, which makes them uniquely useful probes of the intestinal barrier. Low molecular weight PEGs of 200 to 600 grams per mole are clear, viscous liquids that can be absorbed through the gastrointestinal mucosa and excreted unchanged in urine, which is precisely why PEG 400 has long been used in permeability tests to detect barrier alterations in conditions such as celiac disease and chronic inflammatory bowel disease. High molecular weight PEGs, by contrast, such as PEG 3350 and PEG 4000, are waxy solids or powders that pass through the digestive tract essentially untouched, acting as osmotic laxatives by coordinating water molecules in the intestinal lumen.

The pharmacokinetic evidence assembled in the review reveals a striking molecular-weight gradient. Urinary recovery studies, a proxy for systemic absorption, show that low molecular weight PEGs can reach up to 60 percent of an administered dose in healthy humans, and roughly 20 to 36 percent in animals, a phenomenon correlated with solvent drag through aquaporins, the ubiquitous membrane channels that transport water and some solutes during osmotic processes. For PEG 2000, absorption falls below 4 percent. For PEG 3350, reported absorption ranges from 0.01 to 0.28 percent, and for PEGs above 4000 grams per mole it drops below 0.08 percent. Human intestinal perfusion studies using solutions containing 1 gram per liter of PEG 3350 recovered 99 percent and 109 percent of the polymer in the effluent, confirming that it is essentially not absorbed. This pattern is so well established that the ICH M9 guideline on biopharmaceutics-based biowaivers lists PEG 4000 as a zero-permeability model drug for validating Caco-2 cell permeability assays.

The mechanism behind this exclusion is partly thermodynamic. Each ethylene glycol repeat unit binds approximately three water molecules, a strong interaction that dramatically increases the effective steric bulk of the polymer and blocks its paracellular transport through the epithelium. The tight junction architecture imposes a stringent steric limit, typically below 1 nanometer, that excludes polymers the size of PEG 3350 and 4000 even when junctional regulation is disrupted. The review also addresses a clinically important question: what happens in diseased guts? Conditions with mucus depletion, such as active ulcerative colitis, Crohn’s disease, or severe infectious enteritis, may weaken the mucus filter, and mucositis or celiac inflammation can transiently loosen paracellular barriers. Yet even in these settings, evidence indicates that PEGs above 3 to 4 kilodaltons still experience substantial size-dependent exclusion, and no clinical or experimental data support meaningful absorption of high molecular weight PEGs even in critical illness or short-bowel syndrome.

But the review does not stop at a clean verdict. The authors raise a subtle analytical problem that could reinterpret some of the literature: PEGs produced by polymerization are inherently polydisperse, meaning any batch of PEG 3350 or 4000 contains a small residual fraction of low molecular weight chains. The United States Pharmacopeia accepts an impurity level of up to 3 percent for pharmaceutical-grade PEG 3350, with an apparent weight-average molecular weight between 3015 and 3685 grams per mole. This means that the tiny absorbed fractions reported in some studies, the reviewers argue, might actually reflect uptake of low molecular weight impurities rather than the bulk polymer. Supporting this hypothesis, experiments by Winne and Gorig with radiolabeled PEG 4000 in rats showed that the apparent absorbed material consisted mainly of lower molecular weight impurities present in the commercial batches.

The analytical challenge is far from trivial. PEG lacks chromophores, making direct UV-visible detection difficult, and its extreme hydrophilicity causes poor retention on standard C18 HPLC columns. Mass spectrometry struggles with the formation of multiple charge states from protons and metal ions, producing overlapping oligomeric distributions. Liquid chromatography-tandem mass spectrometry remains the gold standard for quantifying PEG in biological matrices at nanogram-per-milliliter sensitivity, while size exclusion chromatography coupled with multi-angle light scattering is preferred for determining absolute molecular weight distributions in quality control, though it is less sensitive. High-resolution mass spectrometry excels at resolving individual oligomers and impurities but demands intensive computation. Pelham and colleagues reported a relative error of 15 percent for serum PEG quantification methods, underscoring how much uncertainty may have crept into older pharmacokinetic measurements that could not distinguish PEG fractions of different chain lengths.

On the therapeutic side, the case for high molecular weight PEGs is strong. By retaining large amounts of water in the intestinal lumen, they soften stool and ease defecation, while the resulting increase in endoluminal pressure indirectly stimulates peristalsis. They are the first recommended treatment for constipation in children, outperforming lactulose, stimulant laxatives such as senna and picosulfate, milk of magnesia, and probiotics in comparative studies. A 2003 safety study tracking 83 children over three months found PEG 3350 therapy clinically and biochemically safe, with similar results reported in infants. Excipients such as sodium, potassium, and bicarbonate maintain isotonicity so that fluid exchange between body and gut remains neutral, and clinical evidence confirms they neither damage the mucosa nor enhance permeability; PEG is recovered unchanged in feces regardless of formulation, with any salts merely accelerating transit by increasing the osmotic load.

The regulatory conclusion follows directly from the pharmacology. Because PEG 3350 and 4000 are neither absorbed nor metabolized in the gastrointestinal tract, they qualify under Rule 21 of Annex VIII of Regulation (EU) 2017/745 as Class IIb substance-based medical devices intended for short-term use of up to thirty days, based on their purely physical, local mechanism of action in the gut. The same non-permeability that makes them safe for daily use also makes them indispensable diagnostic markers of intestinal integrity, in which role they are marketed as medicinal products. The Milan team’s synthesis ultimately reframes a familiar pharmacy-shelf product as a window onto the fundamental architecture of the human intestinal barrier, and as a reminder that in physiology, size really is destiny.

Subject of Research: Gastrointestinal absorption and regulatory classification of high molecular weight polyethylene glycols

Article Title: Oral absorption of high molecular weight polyethylene glycols: mechanistic, safety and regulatory insights

Article References: Gennari, C. G. M., Azari, S., Casiraghi, A., & Musazzi, U. M. (2026). Oral absorption of high molecular weight polyethylene glycols: mechanistic, safety and regulatory insights. Frontiers in Drug Safety and Regulation, 6, Article 1851318. https://doi.org/10.3389/fdsfr.2026.1851318

Image Credits: AI Generated

DOI: 10.3389/fdsfr.2026.1851318

Keywords: polyethylene glycol, PEG 3350, intestinal barrier, osmotic laxatives, macromolecule absorption, tight junctions, medical devices, Regulation EU 2017/745, pharmacokinetics, intestinal permeability, USP impurities, constipation